Two months ago we reported on the first ovarian cancer surgeries performed with fluorescence guidance. As described in the Nature Medicine paper, the international team of researchers from The Netherlands, Germany, and Indiana used folate coupled to fluorescein isothiocyanate (FITC) to make ovarian cancer cells glow so they could be easily identified.
Now, in this week’s issue of Science Translational Medicine, another international team from Japan and Maryland reports their development of a spray-on probe that may provide even better sensitivity and fluorescent contrast than the folate-FITC counterpart. The editors of STM summarize this work well in the following note: Read more »
*This blog post was originally published at Medgadget*
Right off the top, let me be clear that I am NOT minimizing the importance of this week’s news about an experimental treatment for leukemia – one that has drawn much news attention.
It is an important finding.
What I am commenting on herein is the news coverage.
The ABC television piece itself wasn’t bad, with good perspective from Dr. Len Lichtenfeld of the American Cancer Society. But the lead-in and the ending, both involving anchor Diane Sawyer, were hyperbolic. The following screenshot was part of Sawyer’s lead-in. Read more »
*This blog post was originally published at Gary Schwitzer's HealthNewsReview Blog*
British researchers identified a faulty gene associated with a one-in-11 chance of developing ovarian cancer, and they think drugs for breast cancer might also work in these women.
Researchers from England’s Institute of Cancer Research reported that they compared DNA from women from 911 families with ovarian and breast cancer and to a control group of 1,060 people from the general population.
They found eight gene faults in theRAD51Dgene in women with cancer, compared with one in the control group. TheRAD51Dgene repairs damaged DNA, and when it’s faulty, cells are more likely to turn cancerous.
Results appear Read more »
*This blog post was originally published at ACP Internist*
Female models may be tall and beautiful, but they are also at markedly increased risk of developing cancer. The New York Times reported on a fascinating research article regarding height of a women and risk of cancer.
Specifically, for every four-inch increase in height over 5 feet 1 inch, the risk that a woman would develop cancer increased by about 16 percent, especially for:
• Colon Cancer (RR per 10 cm increase in height 1.25, 95% CI 1.19—1.30)
• Rectal Cancer (1.14, 1.07—1.22)
• Malignant Melanoma Read more »
*This blog post was originally published at Fauquier ENT Blog*
In a large multicenter study enrolling over 70,000 women, annual screening with transvaginal pelvic ultrasound and ca125 blood testing did not reduce deaths from ovarian cancer, and in fact led to an increase in complications due to screening.
Investigators in the NCI-sponsored Prostate, Lung and Ovarian Cancer (PLCO) Screening trial randomly assigned over 78,000 women age 55-64 years of age to either annual screening with transvaginal pelvic sonograms for 4 years plus CA125 testing for 6 years or usual care at 10 study sites across the US., and followed the groups for up to 13 years. Over that time period, ovarian cancer rates in the screened group were 5.7 per 10,000 person-years vs 4.7 per 10,000 persons-years in the usual care group, with 3.1 deaths vs 2.6 deaths per 10,000 person years, respectively. Over 3000 women had false positive screening results, a third of whom had surgery and 15% of those operated on had a complications from their surgery. Deaths from other causes did not differ between the groups.
The investigators concluded that annual screening for ovarian cancer does not reduce mortality, and in fact caused harms among women with fals positive abnormal results.
This is not the first study that failed to find efficacy for ultrasound and ca125 in reducing mortality from ovarian cancer, but Read more »
*This blog post was originally published at The Blog That Ate Manhattan*